NCT06011954View on ClinicalTrials.gov

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

RecruitingOBSERVATIONAL
Enrollment

202

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Urothelial Cancer
Interventions
DRUG

Enfortumab Vedotin

Intravenous

Trial Locations (17)

10408

RECRUITING

Site KR82001, Goyang-si

16247

RECRUITING

Site KR82012, Suwon

16500

RECRUITING

Site KR82008, Suwon

21565

RECRUITING

Site KR82004, Incheon

42415

RECRUITING

Site KR82014, Daegu

47392

RECRUITING

Site KR82015, Busan

48108

RECRUITING

Site KR82010, Busan

49201

ACTIVE_NOT_RECRUITING

Site KR82009, Busan

50612

RECRUITING

Site KR82016, Busan

54907

RECRUITING

Site KR82013, Jeonju

58128

COMPLETED

Site KR82007, Jeollanam-do

02841

RECRUITING

Site KR82002, Seoul

03181

RECRUITING

Site KR82005, Seoul

03722

RECRUITING

Site KR82003, Seoul

06351

RECRUITING

Site KR82017, Seoul

07417

RECRUITING

Site KR82006, Seoul

07985

RECRUITING

Site KR82011, Seoul

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Korea, Inc.

INDUSTRY

NCT06011954 - A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection | Biotech Hunter | Biotech Hunter